Formulation Development
Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
Terns Pharmaceuticals, Inc. recently announced the US FDA granted Orphan Drug Designation for TERN-701 for the treatment of chronic myeloid leukemia (CML). TERN-701, the Company’s…
Cellares Unveils First cGMP-Compliant Cell Shuttle in its South San Francisco Center of Excellence
Cellares recently announced the completion of its first current Good Manufacturing Practice (cGMP)-compliant Cell Shuttle. The Cell Shuttle is an automated, ultra-high throughput, cell therapy…
Alcami Partners With Tanvex to Offer a Complete Solution for Biologics Developers
Alcami Corporation recently announced a new strategic partnership with Tanvex CDMO, a biologics developer offering pre-clinical to commercial biologic CDMO services. Through the collaboration, Alcami…
Moa to Develop Next-Gen Bioherbicides in New 10-Year Commercial Partnership With Croda
Deal will accelerate Moa’s development of next-generation bioherbicides, designed to tackle the global threat to food production from increasing weed resistance….
Ajinomoto Bio-Pharma Services Garners Six CDMO Leadership Awards, Further Establishing its Industry Excellence
Ajinomoto Bio-Pharma Services recently received CDMO Leadership Awards in all six categories - Capabilities, Compatibility, Expertise, Quality, Reliability, and Service for both the Overall and…
Ubiquigent Enters Agreement With Astellas Subsidiary, Nanna Therapeutics
Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics….
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for First-in-Class NEK7 Directed Molecular Glue Degrader & NLRP3/IL-1β Pathway Inhibitor
Monte Rosa Therapeutics, Inc. recently announced a novel development candidate, MRT-8102, a potent, highly selective and orally bioavailable NIMA related kinase 7 (NEK7)-directed MGD. MRT-8102…
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
Immuneering Corporation recently announced the first patient has been dosed in the Phase 2a portion of its Phase 1/2a clinical trial of IMM-1-104, its lead…
Acelyrin Announces Positive Top-line Results From Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
ACELYRIN, INC. recently announced its global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) met the primary endpoint of ACR50 at week 16…
Athira Pharma Presents Clinical & Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s & Parkinson’s Diseases
Athira Pharma, Inc. presented new clinical and preclinical data further highlighting the therapeutic potential of fosgonimeton at the AD/PD 2024 International Conference on Alzheimer’s and…
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children With Autism Spectrum Disorder
SciSparc Ltd. recently announced the first patient has been enrolled in the company's clinical trial assessing the efficacy and safety of SCI-210 for the treatment…
NodThera’s NLRP3 Inhibitor Reverses Neuroinflammation in Parkinson’s Disease Phase 1b/2a Trial
NodThera recently announced positive data from its Phase 1b/2a study in Parkinson’s disease patients, evaluating the effects of its oral, brain-penetrant NLRP3 inflammasome inhibitor NT-0796,…
Genezen Announces Strategic Process Development & Manufacturing Partnership Agreement With Seattle Children’s Research Institute
Seattle Children’s Research Institute and Genezen have unveiled a strategic manufacturing partnership for Seattle Children’s Research Institute’s X-linked agammaglobulinemia….
Hovione Partners With Dragonfly Technologies to Offer Micellar Chemistry Technology to Customers as a Sustainable Alternative to Conventional Chemical Processes
Hovione recently announced it has signed an agreement with Dragonfly Technologies, Inc. to gain access to its micellar technology for chemistry-in-water processes, developed by Prof. Bruce…
Adare Pharma Solutions to Expand Packaging & Warehousing Capabilities in Europe
Adare Pharma Solutions recently announced that work has begun to add packaging capabilities and further warehousing capacity at its….
Rentschler Biopharma Contributes to Nearly 25% of FDA-Approved Biopharmaceuticals in 2023
In 2023, the US FDA’s Center for Drug Evaluation and Research (CDER) approved 55 new drugs, 17 of which were biopharmaceuticals. Rentschler Biopharma SE, a…
Olema Oncology Announces Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type & Mutant ER+ Breast Cancer Both as Monotherapy & in Combination With CDK4/6 Inhibitors
Olema Pharmaceuticals, Inc. recently announced that Molecular Cancer Therapeutics, an American Association for Cancer Research journal, has selected as a featured article a data publication that…
BiomX Enters Merger Agreement With Adaptive Phage Therapeutics & Concurrent $50-Million Financing
Acquisition will create phage therapy company with an advanced pipeline with two Phase 2 assets, BX004 for the treatment of chronic pulmonary infections in cystic fibrosis patients and BX211 for the treatment of diabetic foot osteomyelitis….
Exclusive License Agreement Secured With Erganeo for EVerGel, EVerZom's Breakthrough Treatment for Fistulas & Fibrosis of the Digestive Tract
EVerZom, a CNRS/Université Paris Cité spin-off specializing in exosomes, has announced the signature of a second exclusive license agreement with Erganeo for the development of…
Allyx Therapeutics Announces Expansion Into Parkinson’s Disease Clinical Research With Lead Compound Following IND Acceptance
Allyx Therapeutics recently announced the US FDA has accepted its Investigational New Drug Application (IND), enabling the company to proceed with clinical research in Parkinson’s…
